Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) PE Ratio without NRI: 100.96 (As of Jul. 08, 2026) — 28% Below Median


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
78 GF Score
Price €5.25
GF Value €3.29
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co PE Ratio without NRI?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 -3.67% 78 PE Ratio without NRI is 100.96 as of Jul. 08, 2026, which is 28% below its 10-year median of 139.54. GuruFocus rates FRA:I54 with a GF Score™ of 78/100 and a GF Value™ of €3.29 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 265 Biotechnology companies, Biocytogen Pharmaceuticals (Beijing) Co ranks worse than 86.04% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-08), Biocytogen Pharmaceuticals (Beijing) Co's share price is €5.25. Biocytogen Pharmaceuticals (Beijing) Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI for today is 100.96.

During the past 6 years, Biocytogen Pharmaceuticals (Beijing) Co's highest PE Ratio without NRI was 407.91. The lowest was 74.39. And the median was 139.54.

Biocytogen Pharmaceuticals (Beijing) Co's EPS without NRI for the six months ended in Dec. 2025 was €0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.

As of today (2026-07-08), Biocytogen Pharmaceuticals (Beijing) Co's share price is €5.25. Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio (TTM) for today is 100.96.

During the past years, Biocytogen Pharmaceuticals (Beijing) Co's highest PE Ratio (TTM) was 412.71. The lowest was 73.14. And the median was 141.18.

Biocytogen Pharmaceuticals (Beijing) Co's EPS (Diluted) for the six months ended in Dec. 2025 was €0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.

Biocytogen Pharmaceuticals (Beijing) Co's EPS (Basic) for the six months ended in Dec. 2025 was €0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Biocytogen Pharmaceuticals (Beijing) Co PE Ratio without NRI Related Terms


Biocytogen Pharmaceuticals (Beijing) Co PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co PE Ratio without NRI Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial N/A At Loss At Loss 97.91 76.10

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only At Loss At Loss 97.91 At Loss 76.10

FRA:I54 vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI falls into.


FRA:I54
78GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=5.25/0.052
=100.96

Biocytogen Pharmaceuticals (Beijing) Co's Share Price of today is €5.25.
For company reported semi-annually, Biocytogen Pharmaceuticals (Beijing) Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 100.96 mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a PE Ratio without NRI of 100.96 as of Jul. 08, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. This is 28% below median its historical median of 139.54. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI has ranged from 74.39 to 407.91. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #228 out of 265 companies in the Biotechnology industry, placing it in the top 86%.
Is Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI too high?
Biocytogen Pharmaceuticals (Beijing) Co's current PE Ratio without NRI of 100.96 is 28% below median its 10-year median of 139.54. Over the past 10 years, this metric has ranged from a low of 74.39 to a high of 407.91. The Biotechnology industry median PE Ratio without NRI is 25.30. Biocytogen Pharmaceuticals (Beijing) Co's value of 100.96 is 299.1% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #228 out of 265 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #228 out of 265 companies for PE Ratio without NRI. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median PE Ratio without NRI is 25.30. Biocytogen Pharmaceuticals (Beijing) Co's value of 100.96 is 299.1% above this benchmark. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own PE Ratio without NRI has ranged from 74.39 to 407.91 over the past decade. While the company's 10-year median is 139.54 vs. the industry median of 25.30, Biocytogen Pharmaceuticals (Beijing) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.30, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current PE Ratio without NRI of 100.96 is 299.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current PE Ratio without NRI is 100.96, which is 28% below median its own 10-year median of 139.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.29, compared to a current price of €5.25 — trading 59.6% above its estimated fair value. The current PE Ratio without NRI is 100.96, which is 28% below median its 10-year median of 139.54 and 299.1% above the Biotechnology industry median of 25.30. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current PE Ratio without NRI is 100.96 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €5.25 is trading 59.6% above its estimated GF Value™ of €3.29. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for FRA:I54:

  • PE Ratio without NRI: 100.96 (28% below median its 10-year median of 139.54)
  • GF Value™: €3.29 vs. price of €5.25 (59.6% above fair value)
  • GF Score™: 78/100 with 2 warning signs
  • Industry Position: 299.1% above the Biotechnology median (#228 of 265)

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
78GF Score

Get the complete analysis for FRA:I54

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price
€3.29
GF Value